In continuation of our efforts toward the discovery of potent non-nucleoside hepatitis B virus (HBV) inhibitors with novel structures, we have employed bioisosterism and hybrid pharmacophore-based strategy to explore the chemically diverse space of bioactive compounds. Cytotoxicity, anti-HBV antigen secretion activities and anti-HBV DNA replication activity were assayed with cell counting kit-8 (CCK-8)
在继续努力发现具有新颖结构的有效非核苷乙型肝炎病毒(HBV)
抑制剂的过程中,我们采用了
生物立体异构和基于混合药效团的策略来探索
生物活性化合物的
化学多样性空间。使用细胞计数试剂盒8(CCK-8),酶联免疫吸附测定(ELI
SA)和实时PCR分别测定细胞毒性,抗HBV抗原分泌活性和抗HBV DNA复制活性。一些新化合物能够在低微摩尔范围内抑制HBV DNA活性的复制。尤其是,化合物8u对HBV DNA复制表现出最有效的活性,IC50值为3.4μM。研究了这些新化合物的初步构效关系(
SAR),